ADRB1 and breast carcinoma: No synergism was calculated based on combinations of β1-AR and β2-AR antagonists, and these combinations were incapable of recapitulating the anti-proliferative effects of the non-selective β-blocker propranolol, suggesting the potential that off target effects partially contribute to the effectiveness of non-selective beta blockers against breast cancer cell lines.